Investigation of the association between cardio-metabolic risk factors, neurotrophins and gastric hormones among apparently healthy women: A cross-sectional analysis

Introduction: Although, some evidence has shown that obestatin, ghrelin, and neurotrophic factors can be involved in the development of cardio-metabolic risk factors, there are some contradictions in this regard. We aimed to investigate the association of serum neurotrophic factors and some gastric hormones with cardio-metabolic risk factors among apparently healthy women. Methods: In the present study, 90 apparently healthy women were recruited by a convenient sampling method from the nutrition counseling clinic in Tabriz, Iran. All participants need dietary counseling for weight loss and were recruited before receiving any dietary interventions. Anthropometric, biochemical, physical activity, and blood pressure (BP) measurements, as well as dietary assessment, were done in all participants. Results: Women who were in the highest tertile of serum obestatin levels (OR=0.118, 95% CI:0.035-0.396) had a significantly lower risk for development of hypertriglyceridemia compared to the reference group (Ptrend < 0.001). Participants in the highest tertile of serum ghrelin had a significant lower risk of hypertriglyceridemia, hyperglycemia, low HDL-C, and MetS (Ptrend < 0.05). Women who were in the higher tertile of serum NGF levels had a significantly lower risk for development of hypertriglyceridemia after adjustment for potential confounding variables (OR=0.091, 95% CI: 0.023-0.361 and OR=0.193, 95% CI: 0.057-0.649 respectively). Conclusion: In the current study serum levels of obestatin, NGF, and ghrelin were associated with some cardio-metabolic risk factors such as hypertriglyceridemia and MetS. It seems that these factors are associated with metabolic regulation. However, further studies are needed to substantiate this claim.

[1]  P. Havel,et al.  Circulating NGF is correlated with indexes of diabetes progression and P2X3 expression in UCD‐T2DM rats , 2021, The FASEB Journal.

[2]  M. Vinciguerra,et al.  Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy , 2021, International journal of molecular sciences.

[3]  F. Farzadfar,et al.  A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions , 2021, PloS one.

[4]  Y. Tao,et al.  Nerve growth factor in metabolic complications and Alzheimer's disease: Physiology and therapeutic potential. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[5]  P. Lee,et al.  Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome , 2020, Scientific Reports.

[6]  N. Pahlavani,et al.  Effect of Egg Consumption on Blood Pressure: a Systematic Review and Meta-analysis of Randomized Clinical Trials , 2020, Current Hypertension Reports.

[7]  D. Zozulinska-Ziolkiewicz,et al.  Brain-Derived Neurotrophic Factor and Diabetes , 2020, International journal of molecular sciences.

[8]  A. Fekete,et al.  The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic connections , 2019, Journal of Neural Transmission.

[9]  A. Rak,et al.  Effect of ghrelin on the apoptosis of various cells. A critical review. , 2019, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[10]  Claudio Aguayo,et al.  Association between insulin resistance and the development of cardiovascular disease , 2018, Cardiovascular Diabetology.

[11]  Ping Yang,et al.  Ghrelin Ameliorates Angiotensin II-Induced Myocardial Fibrosis by Upregulating Peroxisome Proliferator-Activated Receptor Gamma in Young Male Rats , 2018, BioMed research international.

[12]  M. Wozniak,et al.  Nerve growth factor as an important possible component of novel therapy for cancer, diabetes and cardiovascular diseases. , 2018, Cellular and molecular biology.

[13]  S. Kheirouri,et al.  Decreased Serum Levels of Ghrelin and Brain-Derived Neurotrophic Factor in Premenopausal Women With Metabolic Syndrome , 2018, Laboratory medicine.

[14]  P. M. M. de Moraes-Vieira,et al.  The Impact of Ghrelin in Metabolic Diseases: An Immune Perspective , 2017, Journal of diabetes research.

[15]  Zhe-rong Xu,et al.  Obestatin Plays Beneficial Role in Cardiomyocyte Injury Induced by Ischemia-Reperfusion In Vivo and In Vitro , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[16]  F. Azizi,et al.  Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS) , 2017, JMIR research protocols.

[17]  Prof. Alaa Farajallah,et al.  Ghrelin Structure and It’s Receptors: A Review , 2017 .

[18]  M. Giacca,et al.  Plasma total and unacylated ghrelin predict 5-year changes in insulin resistance. , 2016, Clinical nutrition.

[19]  S. Milani,et al.  Functions of Ghrelin in Brain, Gut and Liver. , 2016, CNS & neurological disorders drug targets.

[20]  R. Kelishadi,et al.  Association of ghrelin with cardiometabolic risk factors in Iranian adolescents: the CASPIAN-III study , 2016, Journal of cardiovascular and thoracic research.

[21]  M. Nourbakhsh,et al.  An Evaluation of Acylated Ghrelin and Obestatin Levels in Childhood Obesity and Their Association with Insulin Resistance, Metabolic Syndrome, and Oxidative Stress , 2016, Journal of clinical medicine.

[22]  M. Ungureanu,et al.  Effects of ghrelin in energy balance and body weight homeostasis , 2016, Hormones.

[23]  K. Shin,et al.  The role of ghrelin in the regulation of glucose homeostasis , 2016, Hormone molecular biology and clinical investigation.

[24]  M. Giacca,et al.  Unacylated Ghrelin Reduces Skeletal Muscle Reactive Oxygen Species Generation and Inflammation and Prevents High-Fat Diet–Induced Hyperglycemia and Whole-Body Insulin Resistance in Rodents , 2016, Diabetes.

[25]  T. Tokudome,et al.  Ghrelin and Blood Pressure Regulation , 2016, Current Hypertension Reports.

[26]  M. El-Saka,et al.  Effect of obestatin on normal, diabetic, and obese male albino rats , 2016 .

[27]  Undurti N. Das,et al.  Brain-derived neurotrophic factor and its clinical implications , 2015, Archives of medical science : AMS.

[28]  Weizhen Zhang,et al.  The Role of Ghrelin in Senescence: A Mini-Review , 2015, Gerontology.

[29]  L. Wood Metabolic dysregulation. Driving the obese asthma phenotype in adolescents? , 2015, American journal of respiratory and critical care medicine.

[30]  F. Palavra,et al.  Biomarkers of Cardiometabolic Risk, Inflammation and Disease , 2015 .

[31]  P. Nikolov,et al.  Expression of leptin, NGF and adiponectin in metabolic syndrome. , 2014, Folia biologica.

[32]  M. Hristova Metabolic syndrome--from the neurotrophic hypothesis to a theory. , 2013, Medical hypotheses.

[33]  M. Puig-Domingo,et al.  Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women , 2012, Clinical endocrinology.

[34]  A. Cui,et al.  Decreased serum obestatin consequent upon TRIB3 Q84R polymorphism exacerbates carotid atherosclerosis in subjects with metabolic syndrome , 2012, Diabetology & Metabolic Syndrome.

[35]  G. Muccioli,et al.  Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms , 2012, Cardiovascular Diabetology.

[36]  S. Nedjat,et al.  The Persian, Last 7-day, Long form of the International Physical Activity Questionnaire: Translation and Validation Study , 2011, Asian journal of sports medicine.

[37]  O. Chevallier,et al.  Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats , 2011, Peptides.